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Abstract Recent successful clinical trials of endovascu-
lar thrombectomy for large artery ischaemic stroke have
established the value of this treatment modality as an
adjunct to intravenous thrombolysis, not as an alternative:
thrombectomy delivery was undertaken in the context of
highly efficient networks for acute thrombolysis delivery
and the great majority of patients received IV thrombolytic
drug treatment. Even for the minority of acute stroke
patients for whom thrombectomy is potentially relevant,
access will be limited by geography and service infras-
tructure. Developments in intravenous thrombolysis in the
near future will likely produce safer and more effective
intravenous treatments. Intravenous thrombolysis will
remain the first line of treatment for the great majority of
acute stroke patients.
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Intravenous thrombolysis (IVT) is an essential enabling
technology for endovascular treatment, but current enthu-
siasm generated by the five endovascular treatment trials
published in 2015 [1–5] should not distract from the wider
reality of acute stroke treatment. For most patients, in most
countries, and in most situations, IVT is the only proven
and necessary therapy.
As indicated in the Pro argument, the great majority of
endovascular treatment was adjunctive to IVT. In the
published trials, only 15 % of patients were considered
ineligible for IVT (and the protocols did not define what
was accepted as ‘‘ineligible’’—clinical practice has already
moved far beyond the narrow licence criteria for alteplase,
and provided solid evidence for the safety and effective-
ness of doing so [6], and there is much subjectivity in
determining ‘‘ineligibility.’’) When the unpublished data
from three further completed endovascular trials
(THRACE, THERAPY and PISTE) are included, the pro-
portion of ‘‘IVT ineligible’’ patients shrinks further, as all
three trials required IVT for inclusion, and only 10 % had
endovascular treatment in the absence of background IVT
[7]. It is also potentially important that the endovascular
trials were conducted in the setting of highly evolved and
efficient networks of acute care, with the onset to treatment
time of 85–127 min for starting IVT reflecting this, but also
emphasizing how different this is from the average expe-
rience of acute stroke thrombolysis worldwide [8, 9]. It is
known that thrombus properties change over time, and that
clot composition may influence the effectiveness of
endovascular therapy [10]. We do not yet know whether
endovascular thrombectomy would be as effective in a
situation where thrombolytic therapy had not been initiated
at such early time points; clot may be intrinsically more
resistant to removal as time passes. Thrombolytic drug
treatment may modify clot composition favorably for
endovascular treatment, but also might have beneficial
effects on distal embolism and also on the microcirculation
after removal of the main target clot, since alteplase causes
prolonged hypofibrinogenaemia and hypoplasmino-
genaemia over many hours [11].
While the results of the SYNTHESIS expansion trial
[12] are disregarded on grounds of older interventional
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technology being deployed (including intra-arterial
thrombolysis in many cases), the absence of any benefit
(and indeed trend towards poorer outcomes) in the intra-
arterial treatment arm should give pause for thought. The
median 1 h additional time taken for treatment initiation in
the intra-arterial treatment arm of this trial seems likely to
represent a major reason for failure. If time is brain, then
initiating effective treatment at the earliest opportunity is
both the ethical and appropriate course of action. Delaying
for ‘‘better’’ treatment may be unnecessary and counter-
productive.
It is often stated by enthusiasts for endovascular
thrombectomy that IVT is ‘‘ineffective’’ for patients with
large artery occlusion, yet evidence does not support this
conclusion. In the IMS-3 trial, IVT alone achieved
recanalization at 24 h in 80 % of proximal M1 occlusions,
86 % of distal M1 occlusions, and 28 % of ICA occlusions,
despite a reduced dose of alteplase being used in a pro-
portion of cases [13]. In addition, 21 % of those random-
ized to endovascular treatment and proceeding to
angiography did not require treatment, in many cases
because an initial proximal occlusion had partially or
completely lysed, raising the concept of ‘‘futile transfer’’—
moving patients to endovascular centers (with potentially
detrimental consequences for outcome) only to find that
recanalization has already occurred. There is therefore no
justification for assuming that endovascular treatment
should be preferred over IVT in any situation where the
patient is eligible for IVT, but rather that IVT should be
initiated as quickly as possible and additional endovascular
treatment delivered once treatment has commenced.
The proportion of patients for whom endovascular
treatment may be suitable is unclear, with estimates based
on trial entry criteria and registries hovering around 5 % of
hospitalized acute ischaemic stroke patients. In the
EXTEND-IA trial, the only one to report a screening log,
1 % of all hospitalized acute ischaemic stroke patients and
7 % of those eligible for IVT were entered into the trial [5].
It seems unlikely that endovascular therapy will be relevant
to more than a small minority of patients even in advanced
healthcare systems and restricted to those patients enjoying
geographical access to appropriate treatment facilities. For
most of the world, including some wealthy countries,
interventional neuroradiology facilities and expertise are a
scarce resource, and the development of necessary infras-
tructure will be both expensive and require time.
Finally, we assume incorrectly that IVT is a fixed entity.
The stroke research community has collectively failed to
address questions about the optimal agent and dosing
regime for IVT, questions that cardiologists in contrast
answered rapidly after initial proof of efficacy for IVT in
myocardial infarction. The standard regime for IVT in
stroke remains that tested in the NINDS trial reported in
1995 [14]. Most trials testing alternative (and pharmaco-
logically superior) thrombolytic agents have tried simul-
taneously to expand the treatment time window or eligible
patient groups, without success [15]. Only recently have
investigator-led efforts to test newer thrombolytic agents
against alteplase, or to evaluate different dosing regimes of
alteplase, begun. Tenecteplase achieves superior recanal-
ization, reperfusion and clinical outcomes in small clinical
trials and with a better safety profile [16, 17]. Larger trials
(ATTEST-2, TASTE, NOR-TEST) are underway to
establish its effects [18]. Lower doses of alteplase might be
as effective, but safer, and are under investigation in
ENCHANTED. Combinations of thrombolytic drugs with
antiplatelet agents or non-invasive physical approaches to
improve clot penetration are also under investigation.
Endovascular devices have evolved significantly over the
course of a few years, and the older devices have proved to
be inferior to the current generation [19, 20]. We should
assume that IVT will evolve in a similar direction.
Better and faster reperfusion is the goal for ischaemic
stroke care, and IV thrombolytic therapy will remain the
base technology for the great majority of patients.
Endovascular treatment is undoubtedly a great advance for
the few who require it, and are able to access treatment
within the necessary timescale, but it is a construction built
on foundations of systems to deliver IVT. Perhaps the
future will identify patients for whom a ‘‘direct to
thrombectomy’’ pathway is better: but for the present this
pathway lacks evidence and should not be the default, even
in the small number of centers where it might conceivably
be provided.
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